312 related articles for article (PubMed ID: 20688287)
1. Non-Hodgkin's lymphoma in patients with human immunodeficiency virus infection in Taiwan.
Yang CJ; Chen MY; Hsieh SM; Sheng WH; Sun HY; Hung CC; Chang SC
J Microbiol Immunol Infect; 2010 Aug; 43(4):278-84. PubMed ID: 20688287
[TBL] [Abstract][Full Text] [Related]
2. Clinical features and predictors of survival of AIDS-related non-Hodgkin's lymphoma in a population-based case series in Sydney, Australia.
Robotin MC; Law MG; Milliken S; Goldstein D; Garsia RJ; Dolan GM; Kaldor JM; Grulich AE
HIV Med; 2004 Sep; 5(5):377-84. PubMed ID: 15369514
[TBL] [Abstract][Full Text] [Related]
3. Kaposi's sarcoma in patients with human immunodeficiency virus infection in Taiwan.
Lin CY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Lo YC; Hung CC; Chang SC
J Microbiol Immunol Infect; 2009 Jun; 42(3):227-33. PubMed ID: 19812856
[TBL] [Abstract][Full Text] [Related]
4. [Non Hodgkin's and Hodgkin's lymphomas and HIV: frequency, outcome and immune response under HAART; Clermont-Ferrand University Hospital, 1991-2003].
Jacomet C; Lesens O; Villemagne B; Darcha C; Tournilhac O; Henquell C; Cormerais L; Gourdon F; Peigue-Lafeuille H; Travade P; Beytout J; Laurichesse H
Med Mal Infect; 2006 Mar; 36(3):157-62. PubMed ID: 16503104
[TBL] [Abstract][Full Text] [Related]
5. AIDS and non-Hodgkin's lymphoma. Experience at an oncological center in Mexico.
Cornejo-Juárez P; Volkow-Fernández P; Avilés-Salas A; Calderón-Flores E
Rev Invest Clin; 2008; 60(5):375-81. PubMed ID: 19227434
[TBL] [Abstract][Full Text] [Related]
6. The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus-related systemic non-Hodgkin lymphoma.
Rossi G; Donisi A; Casari S; Re A; Cadeo G; Carosi G
Cancer; 1999 Dec; 86(11):2391-7. PubMed ID: 10590382
[TBL] [Abstract][Full Text] [Related]
7. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy.
Polesel J; Clifford GM; Rickenbach M; Dal Maso L; Battegay M; Bouchardy C; Furrer H; Hasse B; Levi F; Probst-Hensch NM; Schmid P; Franceschi S;
AIDS; 2008 Jan; 22(2):301-6. PubMed ID: 18097233
[TBL] [Abstract][Full Text] [Related]
8. Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy.
Grau I; Pallares R; Tubau F; Schulze MH; Llopis F; Podzamczer D; Liñares J; Gudiol F;
Arch Intern Med; 2005 Jul; 165(13):1533-40. PubMed ID: 16009870
[TBL] [Abstract][Full Text] [Related]
9. Improvement of systemic human immunodeficiency virus-related non-Hodgkin lymphoma outcome in the era of highly active antiretroviral therapy.
Vaccher E; Spina M; Talamini R; Zanetti M; di Gennaro G; Nasti G; Tavio M; Bernardi D; Simonelli C; Tirelli U
Clin Infect Dis; 2003 Dec; 37(11):1556-64. PubMed ID: 14614680
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.
Lim ST; Karim R; Tulpule A; Nathwani BN; Levine AM
J Clin Oncol; 2005 Nov; 23(33):8477-82. PubMed ID: 16230675
[TBL] [Abstract][Full Text] [Related]
11. The changing pattern of AIDS-defining illnesses with the introduction of highly active antiretroviral therapy (HAART)in a London clinic.
Ives NJ; Gazzard BG; Easterbrook PJ
J Infect; 2001 Feb; 42(2):134-9. PubMed ID: 11531320
[TBL] [Abstract][Full Text] [Related]
12. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta.
Gingues S; Gill MJ
HIV Med; 2006 Sep; 7(6):369-77. PubMed ID: 16903981
[TBL] [Abstract][Full Text] [Related]
13. Outcome in patients with non-hodgkin lymphoma and with or without human immunodeficiency virus infection.
Spina M; Carbone A; Vaccher E; Gloghini A; Talamini R; Cinelli R; Martellotta F; Tirelli U
Clin Infect Dis; 2004 Jan; 38(1):142-4. PubMed ID: 14679461
[TBL] [Abstract][Full Text] [Related]
14. Risk of recurrent nontyphoid Salmonella bacteremia in HIV-infected patients in the era of highly active antiretroviral therapy and an increasing trend of fluoroquinolone resistance.
Hung CC; Hung MN; Hsueh PR; Chang SY; Chen MY; Hsieh SM; Sheng WH; Sun HY; Huang YT; Lo YC; Hsiao CF; Chang SC
Clin Infect Dis; 2007 Sep; 45(5):e60-7. PubMed ID: 17682981
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors after non-Hodgkin lymphoma in patients infected with the human immunodeficiency virus: Aquitaine Cohort, France, 1986-1997. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Thiessard F; Morlat P; Marimoutou C; Labouyrie E; Ragnaud JM; Pellegrin JL; Dupon M; Dabis F
Cancer; 2000 Apr; 88(7):1696-702. PubMed ID: 10738229
[TBL] [Abstract][Full Text] [Related]
16. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy.
Salzberger B; Hartmann P; Hanses F; Uyanik B; Cornely OA; Wöhrmann A; Fätkenheuer G
Infection; 2005 Oct; 33(5-6):345-9. PubMed ID: 16258865
[TBL] [Abstract][Full Text] [Related]
17. High dose therapy and autologous stem cell transplantation for human immunodeficiency virus-associated non-Hodgkin lymphoma in the era of highly active antiretroviral therapy.
Molina A; Krishnan AY; Nademanee A; Zabner R; Sniecinski I; Zaia J; Forman SJ
Cancer; 2000 Aug; 89(3):680-9. PubMed ID: 10931469
[TBL] [Abstract][Full Text] [Related]
18. Changes in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma in the era of highly active antiretroviral therapy: incidence, presentation, treatment, and survival.
Diamond C; Taylor TH; Aboumrad T; Anton-Culver H
Cancer; 2006 Jan; 106(1):128-35. PubMed ID: 16329140
[TBL] [Abstract][Full Text] [Related]
19. Delayed progression to death and to AIDS in a Hong Kong cohort of patients with advanced HIV type 1 disease during the era of highly active antiretroviral therapy.
Wong KH; Chan KC; Lee SS
Clin Infect Dis; 2004 Sep; 39(6):853-60. PubMed ID: 15472819
[TBL] [Abstract][Full Text] [Related]
20. The changing face of HIV-associated lymphoma: what can we learn about optimal therapy inl the post highly active antiretroviral therapy era?
Clayton A; Mughal T
Hematol Oncol; 2004 Sep; 22(3):111-20. PubMed ID: 15991221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
